301 related articles for article (PubMed ID: 28975467)
1. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
3. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
4. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
5. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
7. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
[TBL] [Abstract][Full Text] [Related]
8. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA; Chan J; Datta M; Yee JL; Jain RK
J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
[TBL] [Abstract][Full Text] [Related]
10. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G
Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555
[TBL] [Abstract][Full Text] [Related]
11. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
12. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
[TBL] [Abstract][Full Text] [Related]
13. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
Klobukowski L; Falkov A; Chelimo C; Fogh SE
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
[TBL] [Abstract][Full Text] [Related]
15.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
16. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
18. Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas.
Heo J; Kim SH; Oh YT; Chun M; Noh OK
Neoplasma; 2017; 64(5):803-808. PubMed ID: 28592133
[TBL] [Abstract][Full Text] [Related]
19. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D
J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609
[TBL] [Abstract][Full Text] [Related]
20. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.
Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E
J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
